Lilly’s Zepbound Wins NICE Backing for Obese Patients With Very High BMI 6/5/2024

Companies to Watch for Potential M&As in 2024 6/5/2024

The ABCs of Biopharma This Week: ASCO, BIO and Cancer 6/5/2024

AstraZeneca’s Imfinzi Clinches Late-Stage Victory in Aggressive Lung Cancer 4/5/2024

Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials 4/5/2024

Networking, ADCs and Early Science on the Agenda at AACR 2024 4/5/2024

US National Security, China and Biotechnology in 2024 4/5/2024

Merck Launches Phase III Study for KRAS Hopeful, Eyes Challenge to Amgen and BMS 4/5/2024

FTC Will Have More Time to Review Novo’s $16.5B Catalent Buy 4/5/2024

Boehringer Ingelheim Cuts Staff Due to Low Humira Biosimilar Sales: Reuters 4/5/2024

Novartis to File for Pluvicto Label Expansion After Promising Phase III Data 4/5/2024

Lilly Touts 26% Q1 Revenue Growth on Strong Mounjaro Sales, Raises Full-Year Guidance by $2B 4/30/2024

Pfizer, Genmab’s ADC Tivdak Scores Full FDA Approval in Recurrent or Metastatic Cervical Cancer 4/30/2024

Enlaza Raises $100M in Series A Financing Led by JP Morgan’s Life Sciences Group 4/30/2024

J&J, BMS Lose Challenges to Medicare Drug Price Negotiation Program 4/30/2024

AstraZeneca, Daiichi Sankyo Continue Earlier-Line Breast Cancer Push with Phase III Enhertu Win 4/30/2024

Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership 4/30/2024

Prime Medicine Gets FDA Okay for First Trial of Gene Editing Technique 4/30/2024

A Takeda Oncology Leader’s Passion Fuels A Patient-First Approach 4/30/2024

Ono to Buy Deciphera for $2.4B, Looks to Expand Cancer Pipeline and US Footprint 4/29/2024